Supplementary Figure S6

A

Stomach adenocarcinoma
Overall survival

P=3e-07

High
Low

Days

B

True positive rate

False positive rate

five year (AUC=0.791)
three year (AUC=0.816)
one year (AUC=0.834)

C

Stomach-intestinal adenocarcinoma
Overall survival

P=2e-04

High
Low

Days

D

True positive rate

False positive rate

five year (AUC=0.721)
three year (AUC=0.674)
one year (AUC=0.756)
Supplementary Figure S8

A

Overall survival

P=0.011

Days

High

Low

B

True positive rate

False positive rate

five year (AUC=0.665)

three year (AUC=0.622)

one year (AUC=0.758)

C

Overall survival

P=0.515

Days

High

Low

D

True positive rate

False positive rate

five year (AUC=0.656)

three year (AUC=0.656)

one year (AUC=0.767)

E

Overall survival

P=5e-06

Days

High

Low

F

True positive rate

False positive rate

five year (AUC=0.788)

three year (AUC=0.767)

one year (AUC=0.768)

G

Overall survival

P=0.002

Days

High

Low

H

True positive rate

False positive rate

five year (AUC=0.966)

three year (AUC=0.966)

one year (AUC=0.983)
Supplementary Figure legends

Supplementary Figure S1. Boxplots of methylation β values against risk group in the training dataset.

Supplementary Figure S2. Boxplots of methylation β values against risk group in the testing dataset.

Supplementary Figure S3. Kaplan-Meier and ROC analysis of patients with STAD in sub-groups according to sex, respectively. (A, B) Female sub-group. (C, D) Male sub-group.

Supplementary Figure S4. Kaplan-Meier and ROC analysis of patients with STAD in sub-groups according to age, respectively. (A, B) Age less 65 years sub-group. (C, D) Age over 65 years sub-group.

Supplementary Figure S5. Kaplan-Meier and ROC analysis of patients with STAD in sub-groups according to stage, respectively. (A, B) Early stage sub-group. (C, D) Advanced stage sub-group.

Supplementary Figure S6. Kaplan-Meier and ROC analysis of patients with STAD in sub-groups according to pathological type, respectively. (A, B) Stomach adenocarcinoma sub-group. (C, D) Stomach-intestinal adenocarcinoma sub-group.

Supplementary Figure S7. Kaplan-Meier and ROC analysis of patients with STAD in sub-groups according to metastasis status, respectively. (A, B) Metastasis sub-group. (C, D) No metastasis sub-group.

Supplementary Figure S8. Kaplan-Meier and ROC analysis of patients with STAD in sub-groups according to anatomic site, respectively. (A, B) Antrum/Distal sub-group. (C, D) Cardia/Proximal sub-group. (E, F) Fundus/Body sub-group. (G, H) Gastroesophageal Junction sub-group.